Ganciclovir

更昔洛韦

Report date: 2025/06/17 14:18:11
NME

Base Information

Drug NameGanciclovir
Drug Alias NameDihydroxypropoxymethylguanineVitrasertDENOSINECytoveneRS-21592
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionHuman herpesvirus 1 DNA polymerase inhibitors
TargetsHuman herpesvirus 1 DNA polymerase
Therapy Area/IndicationsSkin MelanomaCNS Embryonal TumorMyelodysplastic Syndromes +[27] 
Global Approved IndicationsCytomegalovirus InfectionsCytomegalovirus Retinitis
Approved Indications in ChinaCytomegalovirus InfectionsCytomegalovirus Retinitis
Original Approved Country/TerritoryJapan
Original Approved Date1988/01/01
Country/TerritoryUnited StatesPuerto RicoNew Zealand +[9] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesMitsubishi Tanabe Pharma Corp
China Registration ClassN/A

Develop Information

Active CompaniesRohto Pharmaceutical Co LtdMurdoch Childrens Research InstituteMitsubishi Tanabe Pharma +[4] 
Inactive CompaniesAdapt Produtos OftalmologicosaLaboratoires Thea SASInstituto De Oncología Ángel H. Roffo +[19] 
Active IndicationsCorneal DiseasesCytomegalovirus InfectionsCytomegalovirus Retinitis
Inactive IndicationsSkin MelanomaCNS Embryonal TumorMyelodysplastic Syndromes +[24] 

Other Information

ATC CodeJ05AB06S01AD09
Related LinksWikipediaDrugBankKEGG